MCID: BNG036
MIFTS: 49

Bone Giant Cell Tumor

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Bone Giant Cell Tumor

MalaCards integrated aliases for Bone Giant Cell Tumor:

Name: Bone Giant Cell Tumor 12 15 17
Giant Cell Tumor of Bone 12 52 58 36 43 71
Osteoclastoma 12 52 58 54
Gct of Bone 52 58
Giant Cell Neoplasm of Bone 12
Giant Cell Tumour of Bone 12
Bone Giant Cell Tumour 12
Giant Cell Myeloma 12

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:4305
KEGG 36 H01470
MeSH 43 D018212
NCIt 49 C121932
SNOMED-CT 67 57500000 697970009
ICD10 via Orphanet 33 D48.0
UMLS via Orphanet 72 C0206638
Orphanet 58 ORPHA363976
UMLS 71 C0206638

Summaries for Bone Giant Cell Tumor

KEGG : 36 Giant-cell tumor of bone (GCTB) is a rare osteolytic tumor of the bone. Although classified as a benign tumor, GCTB is characterized by local aggressiveness and risk of local recurrence. Its name is derived from the numerous multinucleated giant cells found within the tumor, which are principally responsible for the extensive bone resorption that is characteristic of GCTB. However, the neoplastic components of GCTB are the spindle-like stromal cells, which produce RANKL that recruits monocytic osteoclast precursors from blood to the tumor, and stimulates differentiation into multinucleated giant cells. Recently, denosumab (RANKL inhibitor) has become a new treatment option for locally advanced GCTB.

MalaCards based summary : Bone Giant Cell Tumor, also known as giant cell tumor of bone, is related to bone giant cell sarcoma and aneurysmal bone cysts, and has symptoms including pain An important gene associated with Bone Giant Cell Tumor is ACP5 (Acid Phosphatase 5, Tartrate Resistant), and among its related pathways/superpathways are Degradation of the extracellular matrix and Presynaptic function of Kainate receptors. The drugs Denosumab and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include bone, monocytes and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A benign giant cell tumor that results in the presence of multinucleated giant cells.

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 363976 Definition A rare bone sarcoma characterized by a usually benign space-occupying lesion, which is nevertheless locally aggressive and massively damaging to surrounding bone tissue . The tumor is composed of giant multinucleated cells (osteoclast-like cells), mononuclear macrophages, and mononuclear stromal cells which secrete pro-myeloid and pro-osteoclastic factors. Metastasis and malignant transformation are rare, but the recurrence rate is high. Visit the Orphanet disease page for more resources.

Wikipedia : 74 Giant-cell tumor of the bone (GCTOB), is a relatively uncommon tumor of the bone. It is characterized by... more...

Related Diseases for Bone Giant Cell Tumor

Diseases related to Bone Giant Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 228)
# Related Disease Score Top Affiliating Genes
1 bone giant cell sarcoma 32.5 TNFSF11 H3-3B H3-3A
2 aneurysmal bone cysts 31.3 USP6 TNFSF11 CALCA
3 epulis 30.9 SERPINA3 CD68
4 fibroma 30.7 USP6 SERPINA3 CD68
5 telangiectatic osteogenic sarcoma 30.5 USP6 H3-3B
6 ossifying fibroma 30.3 USP6 SH3BP2 SERPINA3 PTH
7 osteomyelitis 30.3 TNFSF11 CTSK CALCA ACP5
8 multicentric carpotarsal osteolysis syndrome 30.2 TNFSF11 TNFRSF11B CTSK ACP5
9 osteonecrosis 30.2 TNFSF11 TNFRSF11B PTH ACP5
10 osteogenic sarcoma 30.2 TNFSF11 TNFRSF11B SPP1 PTH CALCRL
11 grade iii astrocytoma 30.2 THBS1 SERPINA3 CTSB
12 villonodular synovitis 30.1 TNFSF11 CD68 ACP5
13 endosteal hyperostosis, autosomal dominant 30.1 TNFSF11 TNFRSF11B CTSK ACP5
14 osteomalacia 30.0 TNFSF11 PTH CALCA
15 secondary hyperparathyroidism 30.0 TNFRSF11B PTH CALCA ACP5
16 malignant giant cell tumor 29.9 H3-3B H3-3A CD68
17 primary hyperparathyroidism 29.9 TNFSF11 TNFRSF11B PTH CALCA
18 hyperparathyroidism 29.8 TNFSF11 TNFRSF11B PTH CALCA ACP5
19 fibrous dysplasia 29.8 TNFSF11 TNFRSF11B SPP1 SH3BP2 CALCA
20 bone resorption disease 29.8 TNFSF11 TNFRSF11B SPP1 SERPINA3 PTH CTSK
21 connective tissue benign neoplasm 29.7 USP6 SERPINA3 H3-3A CD68
22 cherubism 29.7 USP6 TNFSF11 SH3BP2 SERPINA3 CALCA
23 synovitis 29.7 TNFSF11 TNFRSF11B CD68 ACP5
24 bone cancer 29.6 TNFSF11 TNFRSF11B SERPINA3 PTH CALCA
25 mammary paget's disease 29.6 TNFSF11 TNFRSF11B PTH CTSK CALCA ACP5
26 chondroblastoma 29.5 USP6 TNFSF11 SERPINA3 H3-3B H3-3A
27 osteopetrosis 29.5 TNFSF11 TNFRSF11B CTSK CALCR CALCA ACP5
28 pigmented villonodular synovitis 29.2 TNFSF11 TNFRSF11B SERPINA3 CD68 CALCR ACP5
29 paget's disease of bone 29.1 ZNF687 TNFSF11 TNFRSF11B PTH CALCA ACP5
30 benign giant cell tumor 29.0 USP6 TNFSF11 TNFRSF11B SERPINA3 H3-3B H3-3A
31 bone disease 28.8 TNFSF11 TNFRSF11B SPP1 SERPINA3 PTH CTSK
32 giant cell reparative granuloma 27.9 USP6 TNFSF11 SH3BP2 SERPINA3 PTH CD68
33 paget disease of bone 6 11.3
34 substernal goiter 10.4 PTH CALCA
35 osteopetrosis, autosomal recessive 2 10.4 TNFSF11 CTSK ACP5
36 pycnodysostosis 10.4 TNFSF11 CTSK ACP5
37 adult brain stem glioma 10.4 H3-3B H3-3A
38 congenital epulis 10.3 SERPINA3 CD68
39 xanthogranulomatous pyelonephritis 10.3 SERPINA3 CD68
40 malignant fibrous histiocytoma 10.3
41 fibrous histiocytoma 10.3
42 malignant inflammatory fibrous histiocytoma 10.3 SERPINA3 CD68
43 reticulohistiocytic granuloma 10.3 SERPINA3 CD68
44 pancreas sarcoma 10.3 SERPINA3 CD68
45 polyarticular onset juvenile idiopathic arthritis 10.3 TNFSF11 TNFRSF11B
46 kunjin encephalitis 10.3 H3-3B H3-3A
47 hemophilic arthropathy 10.3 TNFSF11 TNFRSF11B
48 sarcomatoid squamous cell skin carcinoma 10.3 SERPINA3 CD68
49 malignant granular cell myoblastoma 10.3 SERPINA3 CD68
50 periodontitis, chronic 10.3 TNFSF11 TNFRSF11B

Graphical network of the top 20 diseases related to Bone Giant Cell Tumor:



Diseases related to Bone Giant Cell Tumor

Symptoms & Phenotypes for Bone Giant Cell Tumor

UMLS symptoms related to Bone Giant Cell Tumor:


pain

GenomeRNAi Phenotypes related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.74 CTSB
2 Decreased viability GR00055-A-2 9.74 CTSB
3 Decreased viability GR00221-A-1 9.74 TNFRSF11B
4 Decreased viability GR00221-A-2 9.74 ITGAV TNFRSF11B
5 Decreased viability GR00221-A-4 9.74 THBS1
6 Decreased viability GR00249-S 9.74 ACP5 CTSB H3-3B ITGAV SERPINA3 SPP1
7 Decreased viability GR00381-A-1 9.74 CALCA CTSK ITGAV USP6 ZNF687
8 Decreased viability GR00386-A-1 9.74 ITGAV TNFSF11
9 Decreased viability GR00402-S-2 9.74 CTSK THBS1 TNFRSF11B TNFSF11

MGI Mouse Phenotypes related to Bone Giant Cell Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 CALCRL CTSB CTSK H3-3B ITGAV PTH
2 hematopoietic system MP:0005397 10.03 CALCR CALCRL CD68 CTSK ITGAV PTH
3 craniofacial MP:0005382 9.97 CTSK ITGAV PTH SH3BP2 SPP1 THRA
4 immune system MP:0005387 9.97 CALCR CALCRL CD68 CTSB CTSK ITGAV
5 digestive/alimentary MP:0005381 9.87 CALCRL CTSB CTSK ITGAV SH3BP2 THBS1
6 limbs/digits/tail MP:0005371 9.56 CALCR CTSK PTH SH3BP2 THBS1 THRA
7 skeleton MP:0005390 9.32 CALCR CD68 CTSK PTH SH3BP2 SPP1

Drugs & Therapeutics for Bone Giant Cell Tumor

Drugs for Bone Giant Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 4 615258-40-7
2 Immunoglobulins Phase 4
3 Antibodies Phase 4
4 Antibodies, Monoclonal Phase 4
5 Immunoglobulins, Intravenous Phase 4
6 Immunoglobulin G Phase 4
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Phenol Approved, Experimental Phase 3 108-95-2 996
9
Ethanol Approved Phase 3 64-17-5 702
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11 Analgesics Phase 3
12 Cola Phase 3
13 Liver Extracts Phase 3
14 Anesthetics Phase 3
15 Narcotics Phase 3
16 Analgesics, Opioid Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Diphosphonates Phase 3
20 Polymethyl Methacrylate Phase 3
21
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
22
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
23
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
24
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
25
Zoledronic Acid Approved Phase 1, Phase 2 118072-93-8 68740
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 1406-16-2
27 Protein Kinase Inhibitors Phase 2
28 Anti-HIV Agents Phase 2
29 Anti-Infective Agents Phase 2
30 Antiviral Agents Phase 2
31 Interleukin-2 Phase 2
32 Analgesics, Non-Narcotic Phase 2
33 Anti-Retroviral Agents Phase 2
34 Antimetabolites Phase 2
35 Trace Elements Phase 1, Phase 2
36 Micronutrients Phase 1, Phase 2
37 Vitamins Phase 1, Phase 2
38 Hormones Phase 1, Phase 2
39 Nutrients Phase 1, Phase 2
40 Calcium, Dietary Phase 1, Phase 2
41 Calciferol Phase 1, Phase 2
42 Pharmaceutical Solutions Phase 1, Phase 2
43
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
44
Calcium Nutraceutical Phase 1, Phase 2 7440-70-2 271
45
Cyclophosphamide Approved, Investigational Early Phase 1 50-18-0, 6055-19-2 2907
46 Calcium Supplement
47 Immunologic Factors Early Phase 1
48 Alkylating Agents Early Phase 1
49 Immunosuppressive Agents Early Phase 1
50 Antirheumatic Agents Early Phase 1

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
2 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
3 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
5 An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone Completed NCT00396279 Phase 2
6 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone Completed NCT00680992 Phase 2 Denosumab
7 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
8 Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts Completed NCT03415477 Phase 1, Phase 2 Denosumab (Xgeva)
9 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Recruiting NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
10 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
11 A Phase Ib/II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of JMT103 in Surgically Unsalvageable or Refractory Giant Cell Tumor of Bone Not yet recruiting NCT04255576 Phase 1, Phase 2
12 Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study Terminated NCT00889590 Phase 2 Zoledronic acid
13 Phase 2 Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Terminated NCT01564121 Phase 1, Phase 2 acid Zoledronic
14 Il Tumore a Cellule Giganti Delle estermità Completed NCT02996734
15 Giant Cell Tumor of the Bone in Patients Under 15 Years Old: a Single Institution Case-series Active, not recruiting NCT04002817
16 Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China:Correlation Between Recurrence and Drug Withdrawl Not yet recruiting NCT03358212 Denosumab
17 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide

Search NIH Clinical Center for Bone Giant Cell Tumor

Cochrane evidence based reviews: giant cell tumor of bone

Genetic Tests for Bone Giant Cell Tumor

Anatomical Context for Bone Giant Cell Tumor

MalaCards organs/tissues related to Bone Giant Cell Tumor:

40
Bone, Monocytes, Lung, Myeloid, Pancreas, Breast, Lymph Node

Publications for Bone Giant Cell Tumor

Articles related to Bone Giant Cell Tumor:

(show top 50) (show all 1108)
# Title Authors PMID Year
1
Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine. 61
32298199 2020
2
Multiple primary tumors: a case report and review of the literature. 61
32571290 2020
3
Giant Cell Tumor of Bone With Cartilage Matrix: A Clinicopathologic Study of 17 Cases. 61
32412716 2020
4
[Interpretation of 2020 NCCN Clinical Practice Guidelines in Oncology-Bone Cancer]. 61
32498481 2020
5
Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. 61
32320927 2020
6
The two faces of giant cell tumor of bone. 61
32502498 2020
7
[Treatment of giant cell tumor of bone around knee joint with three-dimensional printing personalized prosthesis]. 61
32538567 2020
8
A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response. 61
31743134 2020
9
Does Osteoarticular Allograft Reconstruction Achieve Long-term Survivorship after En Bloc Resection of Grade 3 Giant Cell Tumor of Bone? 61
32469488 2020
10
Expression profiles of miRNAs in giant cell tumor of bone showed miR-187-5p and miR-1323 can regulate biological functions through inhibiting FRS2. 61
32154662 2020
11
CORR Insights®: Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review. 61
32187094 2020
12
Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone. 61
32429739 2020
13
Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? 61
32401001 2020
14
Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review. 61
31794487 2020
15
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. 61
32377818 2020
16
Expression of H3.3 G34W Distinguishes Giant Cell Tumor of Bone From Its Major Giant Cell-containing Bone and Soft Tissue Mimics, in Particular Aneurysmal Bone Cyst and Giant Cell Tumor of Soft Tissue. 61
29489506 2020
17
Functional Outcomes After Sauve-Kapandji Arthrodesis. 61
31948706 2020
18
Functional outcome in giant cell tumor of distal radius treated with excision and fibular arthroplasty: a case series. 61
32358713 2020
19
Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists. 61
32088577 2020
20
Functions of Exogenous RUNX2 in Giant Cell Tumor of Bone In Vitro. 61
32154660 2020
21
Malignant giant cell tumor of bone or soft tissue treated by surgery with or without radiotherapy. 61
32293747 2020
22
Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis. 61
32312263 2020
23
Reconstruction with β-tricalcium phosphate for giant cell tumor of the talus. 61
31743864 2020
24
Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. 61
31748824 2020
25
[Giant cell tumor of bone : Morphology, molecular pathogenesis, and differential diagnosis]. 61
32086536 2020
26
Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. 61
31768625 2020
27
Soft Tissue Special Issue: Giant Cell-Rich Lesions of the Head and Neck Region. 61
31950466 2020
28
Huge aneurysmal bone cyst secondary to giant cell tumor of the hand phalanx: a case report and related literature. 61
32192464 2020
29
Do Massive Allograft Reconstructions for Tumors of the Femur and Tibia Survive 10 or More Years after Implantation? 61
32168064 2020
30
Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. 61
31784095 2020
31
Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience. 61
31862519 2020
32
[Evaluation of total scapular arthroplasty after total scapulectomy for scapular tumors]. 61
32030948 2020
33
Giant cell tumor of bone following denosumab treatment: assessment of tumor response using various imaging modalities. 61
32108273 2020
34
Simvastatin Possesses Antitumor and Differentiation-Promoting Properties That Affect Stromal Cells in Giant Cell Tumor of Bone. 61
31471919 2020
35
Implanted β-Tricalcium Phosphate Blocks Can Function as a Placeholder in Recurrent Giant Cell Tumor of Bone. 61
32015922 2020
36
Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. 61
32539628 2020
37
Locally Aggressive Giant Cell Tumor of Bone With Pulmonary Distant Metastasis and Extrapulmonary Seeding in Pregnancy. 61
32159061 2020
38
Locally Aggressive Giant Cell Tumor of Bone With Pulmonary Distant Metastasis and Extrapulmonary Seeding in Pregnancy. 61
32159067 2020
39
Curettage as first surgery for bone giant cell tumor : adequate surgery is more important than oncology training or surgical management by high volume specialized teams. 61
31520122 2020
40
Role of cancer stem cells in the development of giant cell tumor of bone. 61
32351329 2020
41
Denosumab-treated Giant Cell Tumors of Bone: A Clinicopathologic Analysis of 35 Cases From the French Group of Bone Pathology. 61
31651524 2020
42
Denosumab Therapy Obscures Histological Features of Giant Cell Tumor of Bone. 61
31665371 2019
43
Survival and prognosis in malignant giant cell tumor of bone: A population-based analysis from 1984 to 2013. 61
31667061 2019
44
Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. 61
31285528 2019
45
Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone. 61
31762217 2019
46
Present day controversies and consensus in curettage for giant cell tumor of bone. 61
31736607 2019
47
Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report. 61
31725619 2019
48
Role of intravenous zoledronic acid in management of giant cell tumor of bone- A prospective, randomized, clinical, radiological and electron microscopic analysis. 61
31736608 2019
49
Epidemiologic Characteristics, Clinical Behavior, and Outcome of the Giant Cell Tumor of the Bone: A Retrospective Single-center Study. 61
31970259 2019
50
Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases. 61
31687646 2019

Variations for Bone Giant Cell Tumor

Expression for Bone Giant Cell Tumor

Search GEO for disease gene expression data for Bone Giant Cell Tumor.

Pathways for Bone Giant Cell Tumor

Pathways related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 THBS1 SPP1 ITGAV CTSK CTSB
2
Show member pathways
12.21 PTH CALCRL CALCR CALCA
3
Show member pathways
12.16 TNFSF11 TNFRSF11B CTSK CALCR ACP5
4 11.92 PTH CALCRL CALCR CALCA
5 11.81 CTSK CTSB CD68 ACP5
6 11.76 TNFSF11 TNFRSF11B CTSK CALCR ACP5
7 11.59 TNFSF11 PTH CTSK ACP5
8 11.47 THRA SPP1 PTH
9 11.2 TNFSF11 SPP1 PTH
10 10.82 TNFSF11 TNFRSF11B THRA SPP1 PTH CALCR
11 10.6 TNFSF11 TNFRSF11B PTH ITGAV
12 10.56 TNFSF11 TNFRSF11B SPP1 CTSK ACP5

GO Terms for Bone Giant Cell Tumor

Cellular components related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TNFSF11 TNFRSF11B THBS1 SPP1 SERPINA3 PTH
2 lysosome GO:0005764 9.43 USP6 CTSK CTSB CD68 CALCRL ACP5
3 extracellular region GO:0005576 9.36 TNFSF11 TNFRSF11B THBS1 SPP1 SERPINA3 PTH
4 Barr body GO:0001740 9.32 H3-3B H3-3A
5 endolysosome lumen GO:0036021 9.26 CTSK CTSB

Biological processes related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.86 TNFRSF11B THBS1 SPP1 ITGAV
2 cellular protein metabolic process GO:0044267 9.84 SPP1 H3-3B H3-3A CALCA
3 osteoblast differentiation GO:0001649 9.76 SPP1 H3-3B H3-3A
4 regulation of megakaryocyte differentiation GO:0045652 9.7 THBS1 H3-3B H3-3A
5 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.67 PTH CALCRL CALCR CALCA
6 ossification GO:0001503 9.62 TNFSF11 THRA SPP1 ACP5
7 response to vitamin D GO:0033280 9.61 SPP1 PTH
8 muscle cell differentiation GO:0042692 9.6 H3-3B H3-3A
9 thyroid hormone generation GO:0006590 9.59 CTSK CTSB
10 negative regulation of bone resorption GO:0045779 9.58 TNFRSF11B CALCA
11 response to magnesium ion GO:0032026 9.57 TNFRSF11B THBS1
12 negative regulation of interleukin-12 production GO:0032695 9.55 THBS1 ACP5
13 amylin receptor signaling pathway GO:0097647 9.51 CALCR CALCA
14 negative regulation of smooth muscle contraction GO:0045986 9.49 CALCRL CALCA
15 pericentric heterochromatin assembly GO:0031508 9.48 H3-3B H3-3A
16 negative regulation of dendritic cell antigen processing and presentation GO:0002605 9.46 THBS1 CD68
17 calcitonin gene-related peptide receptor signaling pathway GO:1990408 9.43 CALCRL CALCA
18 regulation of centromere complex assembly GO:0090230 9.4 H3-3B H3-3A
19 negative regulation of chromosome condensation GO:1902340 9.26 H3-3B H3-3A
20 embryo implantation GO:0007566 9.26 SPP1 H3-3B H3-3A CALCA
21 telomeric heterochromatin assembly GO:0031509 9.16 H3-3B H3-3A
22 bone resorption GO:0045453 8.92 TNFSF11 PTH CTSK ACP5

Molecular functions related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 ZNF687 USP6 TNFSF11 TNFRSF11B THRA THBS1
2 cysteine-type endopeptidase activity GO:0004197 9.58 USP6 CTSK CTSB
3 extracellular matrix binding GO:0050840 9.43 THBS1 SPP1 ITGAV
4 fibronectin binding GO:0001968 9.33 THBS1 ITGAV CTSK
5 calcitonin gene-related peptide receptor activity GO:0001635 9.32 CALCRL CALCR
6 calcitonin receptor activity GO:0004948 8.96 CALCRL CALCR
7 proteoglycan binding GO:0043394 8.8 THBS1 CTSK CTSB

Sources for Bone Giant Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....